Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
34.65
+0.24 (0.70%)
At close: Nov 20, 2024, 4:00 PM
34.80
+0.15 (0.43%)
After-hours: Nov 20, 2024, 5:42 PM EST
Exelixis Revenue
Exelixis had revenue of $539.54M in the quarter ending September 30, 2024, with 14.33% growth. This brings the company's revenue in the last twelve months to $2.08B, up 17.31% year-over-year. In the year 2023, Exelixis had annual revenue of $1.83B with 13.60% growth.
Revenue (ttm)
$2.08B
Revenue Growth
+17.31%
P/S Ratio
4.93
Revenue / Employee
$1,589,006
Employees
1,310
Market Cap
9.90B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.83B | 219.15M | 13.60% |
| Dec 31, 2022 | 1.61B | 176.09M | 12.27% |
| Dec 31, 2021 | 1.43B | 447.43M | 45.31% |
| Dec 31, 2020 | 987.54M | 19.76M | 2.04% |
| Dec 31, 2019 | 967.78M | 113.95M | 13.35% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Encompass Health | 5.22B |
| Catalent | 4.42B |
| Charles River Laboratories International | 4.06B |
| Exact Sciences | 2.69B |
| Medpace Holdings | 2.07B |
| Qiagen | 1.97B |
| Sarepta Therapeutics | 1.64B |
| Doximity | 516.85M |
EXEL News
- 13 days ago - Exelixis to Webcast Fireside Chats as Part of Investor Conferences in November - Business Wire
- 21 days ago - Exelixis: Cabometyx Drives Revenue While Zanzalintinib Emerges As Future Growth Engine - Seeking Alpha
- 22 days ago - Exelixis, Inc. (EXEL) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Exelixis Announces Third Quarter 2024 Financial Results and Provides Corporate Update - Business Wire
- 4 weeks ago - 3 Attractive Biotechs With Recent Positives - Seeking Alpha
- 4 weeks ago - Exelixis Stays Strong With Cabometyx While New Assets Approach Key Trials - Seeking Alpha
- 5 weeks ago - Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024 - Business Wire
- 5 weeks ago - Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories - Business Wire